PharmGKB summary: tamoxifen pathway, pharmacokinetics

Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.

Authors

Daniel J Klein¹, Caroline F Thorn, Zeruesenay Desta, David A Flockhart, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University Medical Center, Stanford, California cDepartment of Medicine, Indiana University Simon Cancer Center, Indianapolis, Indiana, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Antineoplastic Agents, Hormonal / metabolism
Antineoplastic Agents, Hormonal / pharmacokinetics*
Antineoplastic Agents, Hormonal / therapeutic use
Arylsulfotransferase / genetics
Arylsulfotransferase / metabolism
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Breast Neoplasms / metabolism
Cytochrome P-450 CYP2D6 / genetics*
Cytochrome P-450 CYP2D6 / metabolism
Female
Humans
Pharmacogenetics
Receptors, Estrogen / antagonists & inhibitors*
Signal Transduction
Tamoxifen / metabolism
Tamoxifen / pharmacokinetics*
Tamoxifen / therapeutic use

Substances

Antineoplastic Agents, Hormonal
Receptors, Estrogen
Tamoxifen
Cytochrome P-450 CYP2D6
Arylsulfotransferase

Grants and funding